Higher Crohn's disease rates with vedolizumab: a study

Published Date: 13 Mar 2023

The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.

Read Full News

Latest News

New GERD Score May Help Clinicians Spot Biggest Symptom

In patients with GERD, dominant symptom intensity is a simple patient-reported measure that identifies the most burdensome symptom and tracks treatment response.

Can a Machine Learning Model Predict Liver Cancer?

Using routine clinical data, the model gauges liver cancer risk better than existing tools, offering a potential way to identify high-risk patients missed by current screening criteria.

IUS May Guide Treatment in Children With Ulcerative Colitis

Intestinal ultrasound scan may serve as an early non-invasive predictor of corticosteroid resistance and short-term colectomy in children with acute severe ulcerative colitis.

Routine EHR Data May Help Predict Pancreatic Cancer Risk

A risk model that uses routine clinical data can identify people at high risk of developing pancreatic cancer over the next 3 years.

Can Romiplostim Reduce Chemo Disruptions in GI Cancer?

A recent analysis assesses whether romiplostim can reduce thrombocytopenia-driven chemotherapy dose reductions, delays, and discontinuations.

Tumor Debulking Fails to Boost Survival in Metastatic CRC

Researchers evaluated whether adding tumor debulking to standard palliative systemic therapy improves survival in patients with multiorgan metastatic colorectal cancer in the ORCHESTRA trial.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Latest News

In patients with GERD, dominant symptom intensity is a simple patient-reported measure that identifies the most burdensome symptom and tracks treatment response.

Using routine clinical data, the model gauges liver cancer risk better than existing tools, offering a potential way to identify high-risk patients missed by current screening criteria.

Intestinal ultrasound scan may serve as an early non-invasive predictor of corticosteroid resistance and short-term colectomy in children with acute severe ulcerative colitis.

A risk model that uses routine clinical data can identify people at high risk of developing pancreatic cancer over the next 3 years.

A recent analysis assesses whether romiplostim can reduce thrombocytopenia-driven chemotherapy dose reductions, delays, and discontinuations.

Researchers evaluated whether adding tumor debulking to standard palliative systemic therapy improves survival in patients with multiorgan metastatic colorectal cancer in the ORCHESTRA trial.

News All Time

Global Study Supports Meat-Free Diets for Cancer Prevention

Observational data on more than 1.8 million people did yield surprises when it came to colorectal and esophageal cancers.

Healthy Midlife Diet Tied to Lower Risk of Cognitive Decline

Greater adherence to the DASH diet and other healthy eating patterns — especially in midlife — is linked to lower risk of cognitive decline later in life, three major US studies show.

CDC Vaccine Advisors to Consider COVID-19 Vaccine Injuries, Long COVID

The U.S. CDC's vaccine advisory committee will discuss and may vote on recommendations ⁠for issues including COVID-19 vaccine injuries and long COVID at its scheduled...

Risankizumab Effective in Crohn's, Real-World Data Show

Risankizumab is effective in inducing clinical and endoscopic remission and is generally well tolerated in patients with Crohn's disease, a real-world study shows.

Rifabutin Regimen Matches Bismuth Regimen in H pylori Rescue

Rifabutin-based triple regimen is noninferior to classical bismuth quadruple regimen as rescue treatment for Helicobacter pylori infection.

Italian Toddler Too Sick for Second Transplant, Doctors Say

An Italian toddler left clinging to life after receiving a damaged donor heart, is not well enough to undergo a second transplant, ⁠a panel of specialists ruled on Wednesday.

Guinea-Bissau Stops Vaccine Study Funded by Trump Administration

Guinea-Bissau's foreign minister has said his government has stopped a study funded by the Trump administration aiming to evaluate side effects of the life-saving hepatitis...

Barrett’s Esophagus Guidance Emphasizes Risk Stratification

Emphasis has shifted to high-quality endoscopy based on patient risk stratification.

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Recommended News For You

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

Asymptomatic or Minimally Symptomatic Myelofibrosis

PSMA PET Beats MRI in Prostate Cancer Staging Study

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

Does diabetes impact the prognosis of people with colorectal cancer?

FDA Approves CAR-T Product Use for Myeloma Early.

Recommended Articles For You

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective 

AI in Genomics: Decoding the Human Genome for Cancer Treatment 

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of cancer is decreased by following international health recommendations.

2.

Resection for Early Liver Cancer Tied to Improved Survival.

3.

Healthcare in the Mix in President Biden's Farewell Address

4.

According to new studies, some cancer patients can safely forego radiation therapy.

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

1.

The Cutting-Edge of Phlebectomy: Redefining Vein Care

2.

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring

3.

Ultimate Guide to Oncology Services in the USA

4.

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review

5.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

5.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot